文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

长效卡博特韦联合利匹韦林治疗失败的危险因素与耐药后果:Dat'AIDS队列研究

Risk Factors and Therapeutic Consequences of Virologic Failure With Long-Acting Cabotegravir Plus Rilpivirine in the Dat'AIDS Cohort.
PubMed 文献 · Clin Infect Dis · 2026-10-14

在法国Dat'AIDS队列中,2196名病毒学抑制的HIV-1成人换用长效卡博特韦联合利匹韦林后中位随访13个月,42人(1.9%)发生病毒学失败,中位103天。26例接受基因型检测者中13例(50%)出现耐药,对多拉韦林敏感性保留率高于多替拉韦/比克替拉韦。高BMI、低CD4最低值、既往抑制不足12个月及历史耐药突变与失败风险独立相关。

要点

  • 长效CAB+RPV病毒学失败率低(1.9%),但失败后约半数出现耐药。
  • 耐药出现时多拉韦林敏感性保留优于多替拉韦/比克替拉韦。
  • 低CD4最低值、既往抑制短、高BMI及历史耐药突变增加失败风险。

核心结论

  • 长效卡博特韦联合利匹韦林维持治疗病毒学失败发生率低,耐药出现罕见,但一旦耐药主要影响比克替拉韦/多替拉韦而非多拉韦林。

研究设计与样本

  • 法国Dat'AIDS队列多中心观察性研究,纳入2021年12月至2023年12月换用长效CAB+RPV的病毒学抑制HIV-1成人,共2196人,中位随访13个月。

主要发现

  • 42人(1.9%)发生病毒学失败,中位发生时间103天。
  • 26例接受基因型检测的失败者中13例(50%)出现耐药。
  • 耐药出现时对多拉韦林敏感性保留率(ANRS 92%,Stanford 96%)高于多替拉韦/比克替拉韦(ANRS 58%,Stanford 65%)。
  • 13例耐药者中7例发生在低水平病毒血症或短暂反弹后重新抑制期间。
  • 多因素分析显示高BMI(aHR 1.07;95%CI 1.01-1.14)、CD4最低值<200 cells/mm3(aHR 2.44;1.31-4.56)、既往抑制<12个月(aHR 2.39;1.01-5.19)及历史CAB/RPV耐药突变与病毒学失败独立相关。

临床怎么用

  • 选择长效CAB+RPV候选者时应评估CD4最低值、既往病毒学抑制时长、BMI及历史耐药突变。
  • 发生病毒学失败时,即使低水平病毒血症也应尽早进行耐药检测。
  • 耐药后若需更换方案,多拉韦林可能比多替拉韦/比克替拉韦保留更多敏感性。

局限性

  • 观察性研究设计,可能存在残余混杂。
  • 病毒学失败病例数较少(42例),基因型检测仅26例。
  • 中位随访13个月,长期失败与耐药风险需更长时间评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-acting cabotegravir plus rilpivirine (CAB + RPV LA) is highly effective as maintenance therapy in virologically suppressed people with HIV (PWH), but virologic failure (VF) may lead to resistance and compromise future antiretroviral options. METHODS: We conducted a multicenter observational study within the French Dat'AIDS cohort, including HIV-1 virologically suppressed adults who switched to CAB + RPV LA between December 2021 and December 2023. VF was defined as two consecutive HIV-1 RNA >50 copies/mL or one >200 copies/mL. Remaining options were interpreted using ANRS and Stanford algorithms. Cox models identified factors associated with VF. RESULTS: Among 2,196 participants followed for a median of 13 months, VF occurred in 42 individuals (1.9%) after a median of 103 days. Among 26 VF cases undergoing genotype, resistance emerged in 13 (50%), with susceptibility maintained more often for doravirine (ANRS 92%, Stanford 96%) than for dolutegravir/bictegravir (ANRS 58%, Stanford 65%). Resistance also emerged during low-level viremia or transient rebound with re-suppression (7/13 cases). In multivariable analysis, higher BMI (aHR 1.07; 95%CI 1.01-1.14), nadir CD4 < 200 cells/mm3 (aHR 2.44; 1.31-4.56), and prior suppression <12 months (aHR 2.39; 1.01-5.19) were independently associated with VF. Historical CAB and RPV RAMs also increased VF risk. CONCLUSIONS: CAB + RPV LA was associated with low incidence of VF and rare resistance emergence. When resistance occurred, it primarily compromised bictegravir/dolutegravir rather than doravirine. Low nadir CD4, shorter prior suppression, higher BMI, and historical CAB and/or RPV RAMs support individualized candidate selection and early resistance testing, even during low-level viremia.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Deschanvres C, Hocqueloux L, Cabié A, et al. Risk Factors and Therapeutic Consequences of Virologic Failure With Long-Acting Cabotegravir Plus Rilpivirine in the Dat'AIDS Cohort. Clin Infect Dis. 2026. PMID: 42873188. doi:10.1093/cid/ciag654

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。